Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent and acceptable proof of identity.~* Male or female subjects ≥19 to 65 years of age of any race or ethnic origin.~* Not currently pregnant, breastfeeding or planning on becoming pregnant; use of contraception as follows:~* Males - those that are sexually active must use a double barrier method of contraception (condom with spermicide) from the first dose of asenapine until 12 weeks after last dose of asenapine~* Women of child-bearing potential - must have a negative urine pregnancy test and confirmed (by the investigator) use of a highly effective form of birth control for 3 months before enrollment and until 12 weeks after their last dose of asenapine.~* Women of non-child bearing potential - women who are either permanently sterilized (hysterectomy, bilateral oophorectomy and bilateral salpingectomy but excluding bilateral tubal occlusion) or who are postmenopausal.~* Diagnosis of PTSD (DSM-IV-TR criteria; confirmed by MINI and CAPS).~* Total CAPS score \> 45.~* Currently taking an approved antidepressant at acceptable dose for 8 weeks or more with non-remission of symptoms.~* No substance use disorders of dependence (except for nicotine, caffeine) in previous 4 wks.~* No substance use disorders of abuse (except for nicotine and caffeine) in the previous 2 wks.~* Physical and laboratory panel (within past one year) are within normal limits or not clinically significant~Exclusion Criteria:~* Lifetime history of bipolar I, schizophrenia, schizoaffective or cognitive disorders (assessed by the MINI)~* Actively considering plans of suicide or homicide (assessed by clinical interview)~* Psychotic symptoms that in the investigator's opinion impair the subject's ability to give informed consent~* A contraindication to the use of asenapine or antidepessant~* Intolerable side effects or allergic reaction to asenapine or the current antidepressant~* Women planning to become pregnant or breastfeed during the study~* Clinically significant unstable or severe medical condition that would contraindicate study participation or expose them to an undue risk of a significant adverse event, including but not limited to: unstable or severe hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease; hypo- or hyperthyroidism, unless the condition has been stabilized; or a history of seizures (except for a single childhood febrile seizure, posttraumatic, or alcohol withdrawal). The following are exclusionary: platelets \< 75,000/mm; hemoglobin \<9g/dL; neutrophils, absolute \< 1000/mm; LFTs \> 3x upper limit; creatinine \> 2 mg/dL; diastolic BP \< 60 or \> 110mmHg; EKG QTc \> 475 msec.~* In regard to vulnerable patient populations, persons with dementia, minors (\<age 19), the elderly (\>age 65), prisoners and the terminally ill are excluded.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- antidepressant plus asenapine (Type: EXPERIMENTAL): adjunctive asenapine

Based on this trial design, predict the completion outcome and termination type (if applicable).